Clinical Trials/NCT00061425

NCT00061425

Completed

Phase 1

Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG

Gilead Sciences0 sitesAugust 2000

ConditionsNon-Hodgkin's Lymphoma Lymphoma, B-Cell

Drugsradiolabeled epratuzumab

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Non-Hodgkin's Lymphoma
Sponsor: Gilead Sciences
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

Registry

clinicaltrials.gov

Start Date

August 2000

End Date

November 2007

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Gilead Sciences

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Phase 1

Safety Study of NHL With 90Y-hLL2 IgGNHLB-cell NHLNon-Hodgkins Lymphoma

NCT00421395Gilead Sciences59

Terminated

Phase 1

Study of 90Y-hLL2 to Treat Non-Hodgkin's LymphomaNon-Hodgkins Lymphoma

NCT00054834Gilead Sciences27

Completed

Phase 1

Safety Study of 90Y-hMN14 to Treat Colorectal CancerColorectal CancerColon CancerRectal CancerColorectal NeoplasmsColorectal CarcinomaColorectal Tumor

NCT00040599Gilead Sciences72

Completed

Phase 1

Safety Study of 90Y-hMN14 to Treat Pancreatic CancerPancreatic Neoplasms

NCT00041639Gilead Sciences75

Completed

Phase 1

Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin LymphomaNon-Hodgkin Lymphoma

NCT00302757University Hospital Tuebingen60